With this double-digit growth trend in mind, we asked three of our Motley Fool contributors which cancer treatment stocks they think are worth buying this month. They picked Geron (NASDAQ:GERN), AbbVie (NYSE:ABBV), and Exelixis (NASDAQ:EXEL). Here's why.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,